ARO-DIMER-PA — Initial data
2H 2026
ARO-DIMER-PA targeting PCSK9 and APOC3 first clinical readout in 2H 2026Source filing
ARWR biotech catalysts & pipeline
ARROWHEAD PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
REDEMPLO (plozasiran) — NDA/BLA submission
Late 2026
Arrowhead is on schedule to submit a sNDA for plozasiran in sHTG to the FDA by year-end 2026 and plans to seek regulatory approval with additional global regulatory authorities thereafter.Source filing